

## Prevention & Treatment of Hepatitis and Chronic Liver Disease

**Dallas, Texas September 23, 2023**

<b>Conference Location</b>	Renaissance Dallas-Addison 15201 Dallas Pkwy Addison, Texas 75001	Phone: (972) 386-6000 <a href="https://www.marriott.com/en-us/hotels/dalic-renaissance-dallas-addison-hotel/overview">https://www.marriott.com/en-us/hotels/dalic-renaissance-dallas-addison-hotel/overview</a>
----------------------------	---	--

<b>Parking at the Conference</b>	Discounted Self-Parking of \$10,00 per day has been arranged for all participants. Please bring your parking ticket to the seminar registration desk to receive this rate.
----------------------------------	---

<b>Driving Directions</b>	<ul style="list-style-type: none"> <li>Take I-35-E North</li> <li>Follow Dallas North Tollway N to Dallas Pkwy in Addison. Take the exit toward Belt Line Rd/Arapaho Rd from Dallas North Tollway</li> <li>Take the exit toward Belt Line Rd/Arapaho Rd</li> <li>As you approach Arapahoe Road, the road will turn to the left, Stay on Dallas Parkway. The hotel will be on your right.</li> </ul>
---------------------------	---

<b>Seminar Agenda and Syllabus Information</b>	Registration begins at <b>7:30 a.m.</b> in the Lalique Ballroom  <b>The Hepatitis and Chronic Liver Disease seminar is a paperless program.</b> The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet or personal computer. Instructions to download the <i>App</i> will be provided. Wi-Fi available without charge.
--	---

<b>Pre-Program Activities</b>	<b>Pre-Lecture 1 – Viral Hepatitis</b> –A summary for discovery and natural history of HCV 60 min <b>Pre-Lecture 2 - End Stage Liver Disease:</b> An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min
<b>7:30 am</b>	<i>Registration and View Exhibits</i>
<b>8:00 am</b>	<b>Opening Comments and Pre-Test</b>
<b>8:20 am</b>	<b>Advances in the Screen and Treatment of HCV</b> <ul style="list-style-type: none"> <li>Highlight of Pre-Lecture 1</li> <li>Screening and Treatment of HCV</li> <li><b>Clinical Cases and Discussion</b></li> </ul>
<b>9:05 am</b>	<b>Hepatitis B: Epidemiology, Natural History and Testing</b> <ul style="list-style-type: none"> <li>The epidemiology of the Hepatitis B infection</li> <li>Efficacies and opportunities in HBV testing and vaccination</li> <li>Anti-viral therapies of HBV</li> <li>The growing relationship between HBV and HDV</li> </ul>
<b>9:35 am</b>	<b>Delta Hepatitis and Hepatitis E Update</b> <ul style="list-style-type: none"> <li>Worldwide perspective and promising research studies</li> <li>Real world outcome studies on HDV and HEV</li> </ul>
<b>10:05 am</b>	<i>Break and View exhibits</i>
<b>10:20 am</b>	<b>End Stage Liver Disease: Recap and Clinical Cases</b> <ul style="list-style-type: none"> <li>A review of Pre-course lecture on end-stage liver disease</li> <li>Clinical cases to illustrate HE and Thrombocytopenia</li> </ul>
<b>10:55 am</b>	<b>Hepatocellular Carcinoma(HCC)</b> <ul style="list-style-type: none"> <li>Screening diagnostic serum assays and imaging tests</li> <li>Treatment and management options: Ablation, TACE and Surgery</li> </ul>

11:35 am	<b>Hepatocellular Carcinoma: New Systemic Treatment Options</b> <ul style="list-style-type: none"> <li>• <b>A case-based approach to HCC treatment</b></li> <li>• Current FDA-Approved Therapies New chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC</li> </ul>
12:10 pm	<b>Luncheon and Product Information Session</b>
1:00 pm	<b>Cholestatic Liver Disease: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis</b> <ul style="list-style-type: none"> <li>• Epidemiology of PSC and Ursodiol and Antibiotic Treatments</li> <li>• Predicting outcomes and Improving Survival in PSC patients</li> <li>• Causes and Markers of PBC Ursodeoxycholic Acid (UDCA) and Obeticholic Acid</li> </ul>
1:40 pm	<b>Alcohol Associated Liver Disease</b> <ul style="list-style-type: none"> <li>• The growing prevalence of alcohol over-consumption and its impact on liver health Warning signs and intervention in alcohol-associated hepatitis</li> </ul>
2:10 pm	<b>Fluid Management, Ascites and Hepatorenal Syndrome</b> <ul style="list-style-type: none"> <li>• The diagnosis and treatment of ascites</li> <li>• How cirrhosis can lead to portal hypertension, ascites, kidney disease and hepatorenal syndrome</li> <li>• New and emerging treatment approaches for of HRS</li> </ul>
2:45 pm	<b>Break &amp; View Exhibits</b>
3:00 pm	<b>NAFLD and NASH: The new healthcare epidemic</b> <ul style="list-style-type: none"> <li>• Epidemiology, Demographics and Diagnosis</li> <li>• Scoring, Staging and Management of Fatty Liver Disease</li> <li>• The ‘unhealthy’ rise in Fatty Liver Disease in the US population and What can be done</li> <li>• Treatment options for thrombocytopenia; including alternatives to platelet transfusion.</li> </ul>
3:30 pm	<b>NASH Treatments in Practice and in Development</b> <ul style="list-style-type: none"> <li>• Current therapies for NASH including Updates from AASLD and EASL</li> <li>• Lifestyle changes as a therapy</li> <li>• Drugs in clinical development for NASH NASH Diagnosis and Treatment cases</li> </ul>
4:15 pm	<b>Closing Comments, Post-test and Wrap-Up</b> Program adjourns at 4:30 pm
Post-program activities	<b>Lecture 3 - SARS-CoV-2 and its Effect on the Liver – 45 minutes</b> <b>Lecture 4 - Overcoming barriers to liver health in special populations - 45 minutes</b>

**Attendee Cancellation, Substitution, Refund**

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

**Recording and Photography**

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

**Attendance Policies**

**Guest Attendance**

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

**Conference Modification or Cancellation**

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

---

**CME Information**

**Physicians (MD/DO)** - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)<sup>™</sup>**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses** - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-24-1318. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

**Nurse Practitioners and Physician Assistants** - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)<sup>™</sup> organizations accredited by ACCME.

---

**JACQUELINE O'LEARY, MD, MPH**

Dr. Jacqueline O'Leary began her pursuit of research as an undergraduate at Stanford investigating drug development, continued at UCSF where she received her MD with thesis for work in cellular and molecular biology. Following her internal medicine residency at UT Southwestern in Dallas,

Dr. O'Leary did a GI fellowship and transplant Hepatology fellowship at Massachusetts General Hospital. Her post-doctoral research there at Harvard focused on immunology. Afterward, she completed a Master's in Public Health from the Harvard School of Public Health.

These accomplishments make her uniquely poised to translate research findings into clinical care. She has focused her clinical research in transplant hepatology, viral hepatitis, and Acute-on-Chronic Liver Failure and is currently the Chief of Hepatology at the Dallas VA Medical Center.

**Your Seminar Faculty****ARJMAND MUFTI, MD**

Dr Mufti is an Associate Professor of Internal Medicine and Medical Director of the Living Donor Liver Transplant Program at UT Southwestern Medical Center. He also serves as the Gastroenterology Fellowship Program Director.

Dr. Mufti earned his medical degree with honors at United Medical and Dental Schools of Guy's and St. Thomas' Hospitals in London. He then trained in internal medicine at Kings College Hospital in London. After finishing a research fellowship at the University of Michigan, he completed residency in internal medicine at the University of Chicago, where he also received advanced training in

gastroenterology and transplant hepatology through separate fellowships. Dr. Mufti's clinical role is as a hepatologist and liver transplant physician and his specialist interests include liver transplantation as well as the management of portal hypertension and complications of chronic liver disease.

**AMIT SINGAL, MD**

Dr. Singal completed fellowships in Gastroenterology and Transplant Hepatology as well as a master's in Health and Healthcare Research from the University of Michigan. After graduating in 2010, he joined faculty at UT Southwestern Medical Center to build the hepatocellular carcinoma (HCC) program. He is currently an Associate Professor of Medicine, Medical Director of the UT Southwestern Liver Tumor Program, and Clinical Chief of Hepatology at UT Southwestern.

He is an expert in hepatocellular carcinoma and has obtained independent NIH funding, DOD funding, and state-level funding examining the HCC care continuum, ranging from HCC prevention to screening and early detection to treatment and survivorship.